参芪扶正液联合EP方案对NSCLC患者生存质量的影响

目的观察参芪扶正注射液联合EP方案治疗晚期非小细胞肺癌的疗效和毒副作用。方法治疗组35例，对照组35例，均采用相同的EP化疗方案，足叶乙甙（VP-16）120mg／m^2静脉滴注，第1-3d，顺铂（PDD）60mg静脉滴注，第1d，每21d为1个周期。3个周期为1个疗程。治疗组化疗期间常规静脉滴注参芪扶正注射液250ml，每日1次，连用14d为1个周期。3个周期为1个疗程。观察两组近期疗效，化疗后生活质量评价、血液毒性反应及免疫功能变化情况。结果参芪扶正注射液配合化疗组总有效率（45．7％）较单纯化疗组（42．9％）高，但差异无统计学意义（P〉0．05），在改善患者生活质量、减轻化疗毒性方面明显优于单纯化疗组，差异有统计学意义（P〈0．05）.治疗组其细胞免疫功能有不同程度提高，而对照组免疫能力下降，差异有统计学意义（P〈0．05）。结论参芪扶正注射液联合EP方案治疗晚期非小细胞肺癌可降低化疗对患者的毒副反应，提高机体免疫功能，改善患者的生活质量。

Observation on the impact of Shenqifuzheng injection in combination with EP therapy on life quality of patients with NSCLC

Aim To observe the effect and toxicity of Shenqifuzheng injection combined with EP regimen on non-small cell lung cancer （NSCLC） af advance stage. Methods Seventy patients were randomly divided into treatment group and control group each consisted of,35 cases. Results The total effective rates of treatment group and control group were47.5% and 42.9% respectively,without significant difference between the two group （P〉0.05）; The life quality and gastrointestinal reactions in treatment group were superior to the patients in control group （P〈0.05）. Conclusions Shenqifuzheng injection combined with EP terapy is effective on NSCLC patients at advanced stage .